Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Toast Inc. Class A Common Stock (TOST) Price & Performance

Cassava Sciences IncTrade
Toast Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Toast Inc. Class A Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while Toast Inc. Class A Common Stock trades at $30 (market cap $17.25B). The key difference: Toast Inc. Class A Common Stock is far larger — about 488.1× Cassava Sciences Inc's market cap, and Toast Inc. Class A Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Toast Inc. Class A Common Stock for 0 Days on average.

FLNATOST
Market Cap
$35.34M$17.25B
Volume
251,94610,274,535
Sector
HealthTechnology
52-Week High
$4.64$39.02
52-Week Low
$0.68$22.33
Typical Hold Time
38 Days0 Days
Enterprise Value
-$47.34M$15.50B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.

Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.

Toast Inc. Class A Common Stock

Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.

The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLNA
52% Buy48% Sell
Avg holding period · 38 Days
TOST
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA →

About Toast Inc. Class A Common Stock

Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.

Read more on TOST →